Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B

Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2003, Pages 917-920

  Silvestri, Romano ^a   La Regina, Giuseppe ^a   De Martino, Gabriella ^a   Artico, Marino ^a   Befani, Olivia ^a   Palumbo, Marianna ^a   Agostinelli, Enzo ^a   Turini, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N METHYL N BENZYLAMINOMETHYL) 1H PYRROLE; 2 (N METHYL N PROPARGYLAMINOMETHYL) 1H PYRROLE; AMINE OXIDASE (FLAVIN CONTAINING); CLORGYLINE; IPRONIAZID; METHYLENEAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N 4 FLUOROBENZYL 1H PYRROLE 2 CARBOXAMIDE; N CYCLOHEXYLMETHYL 1H PYRROLE 2 CARBOXAMIDE; N PROPARGYL 1H PYRROLE 2 CARBOXAMIDE; PYRROLE DERIVATIVE; SELEGILINE; TETRINDOL; TOLOXATONE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; STRUCTURE ANALYSIS;

ALKYNES; AMIDES; AMINES; ANIMALS; BRAIN; CATTLE; ISOENZYMES; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037435063     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0256124     Document Type: Article

References (32)

1. Mondovi, B. Structure and function of amine oxidases; CRC Press: Boca Raton, FL, 1985.
2. Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembenek, M. E.; Kwan, S. W.; Seeburg, P. H.; Shih, J. C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4934-4938.
3. Abell, C. W.; Kwan, S.-W. Molecular characterization of monoamine oxidases A and B. Prog. Nucleic Acid Res. Mol. Biol. 2001, 65, 129-156.
4. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem. 1990, 55, 1166-1169.
5. Binda, C.; Newoton-Vinson, P.; Hubálek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002, 9, 1-5.
6. Morón, J. A.; Campillo, M.; Perez, V.; Unzeta, M.; Pardo, L. Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: biological activities, 3D-QSAR/ CiMFA analysis, and computational simulation of ligand recognition. J. Med. Chem. 2000, 43, 1684-1691.
7. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4743-4758.
8. Shih, J. C.; Chen, K.; Ridd, M. J. Monoamine oxidase: from genes to behaviour. Annu. Rev. Neurosci. 1999, 22, 197-217.
9. Checkoway, H.; Franklin, G. M.; Costa-Mallen, P.; Smith-Weller, T.; Dilley, J.; Swansons, P. D.; Costa L. G. A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology 1998, 50, 1458-1461.
10. Andrews, J. M.; Nemeroff, C. B. Contemporary management of depression. Am. J. Med. Chem. 1994, 97, 24S-32S.
11. Hardman, J. G.; Limprid, L. E.; Goodmal Gilman, A. Drugs and the treatment of psychiatric disorders. In Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed.; Hardman, J. G., Limbird, L. E., Goodman Gilman, A., Eds.; McGraw-Hill: New York, 2001; Chapter 19, pp 450-483.
12. Shelton, R. C. Antidepressant therapy: new targets for drug development. Expert Opin. Ther. Pat. 2001, 11, 1693-1711.
13. Ban, T. A. Pharmacotherapy of depression: a historical analysis. J. Neural Transm. 2001, 108, 707-716.
14. Blackwell, B. Adverse effects of antidepressant drugs. 1. Monoamine oxidase inhibitors and tricyclics. Drugs 1981, 21, 201-219.
15. Bieck, P. R.; Antonin, K.-H. Tyramine potentiation during treatment with MAOIs. In Clinical Advances in Monoamine Oxidase Inhibitor Therapies; Kennedy, S. H., Ed.; American Psychiatric Press: Washington, DC, 1994; pp 83-110.
16. Curet, O.; Damoiseau, G.; Aubin, N.; Sontag, N.; Rovei, V.; Jarreau, F.-X. Befloxatone, a new reversible and selective monoamino oxidase A inhibitor. J. Pharmacol. Exp. Ther. 1996, 277, 253-264.
17. Medvedev, A. E.; Kirkel, A. A.; Kamyshanskaya, N. S.; Moskvitina, T. A.; Axenova, L. N.; Gorkin, V. Z.; Andreeva, N. I.; Golovina, S. M.; Mashkovsky, M. D. Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem. Pharmacol. 1994, 47, 303-308.
18. Drukarch, B.; van Muiswinkel, F. L. Drug Treatment of Parkinson's Disease. Biochem. Pharmacol. 2000, 59, 1023-1031.
19. Cesura, A. M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 1992, 33, 171-297.
20. Walkinshaw, G.; Waters, C. M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 1995, 95, 2458-2464.
21. (a) Stefancich, G.; Artico, M.; Corelli, F.; Silvestri, R.; De Feo, G.; Mazzanti, G.; Durando, L.; Palmery, M. Ricerche su nuovi agenti psicotropi. Sintesi ed attività farmacologica di derivati della 5H-imidazo[2,1-c][1,4]benzodiazepina (Research on novel psychotropic agents. Synthesis and pharmacological activity of derivatives of 5H-imidazo[2,1-c][1,4]benzodiazepine). Farmaco, Ed. Sci. 1985, 40, 429-441.
22. (b) Artico, M.; Corelli, F.; Massa, S.; Stefancich, G.; Avigliano, L.; Befani, O.; Marcozzi, G.; Sabatini, S.; Mondovi, B. Inhibition of copper-dependent amine oxidases by some hydrazides of pyrrol-1-ylbenzoic and pyrrol-1-ylphenylacetic acids. J. Med. Chem. 1988, 31, 802-806.
23. (c) Stefancich, G.; Silvestri, R. Research on nitrogen containing heterocyclic compounds. XVI. Synthesis of 1,3,4,14b-tetrahydro-2,10-dimethyl-2H,10H-pyrazino-[2,1-d]pyrrolo[1, 2-b][1,2,5]benzotriazepine (1:1) maleate (10-methyl-10-azaaptazepine). J. Heterocycl. Chem. 1989, 26, 745-746.
24. (d) Stefancich, G.; Artico, M.; Silvestri, R.; Pantaleoni, G. C.; Giorgi, R.; Palumbo, G. Research on psycotropic agents. III. Antidepressant activity and neuropsycobehavioural effects of new 5H-pyrrolo[1,2-b][1,2,5]benzotriazepine derivatives. Farmaco 1990, 45, 7-27.
25. (e) Morpurgo, L.; Agostinelli, E.; Mondovi, B.; Avigliano, L.; Silvestri, R.; Stefancich, G.; Artico, M. Bovine serum amine oxidase: half-site reactivity with phenylhydrazine, semicarbazide, and aromatic hydrazides. Biochemistry 1992, 31, 2615-2621.
26. (f) Artico, M.; Silvestri, R.; Stefancich, G.; Avigliano, L.; Di Giulio, A.; Maccarrone, M.; Agostinelli, E.; Mondovi, B.; Morpurgo, L. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. Eur. J. Med. Chem. 1992, 27, 219-228.
27. (g) Stefancich, G.; Artico, M.; Silvestri, R. Research on psycotropic agents. IV. Synthesis and neuropsychopharmacological effects of 1,3,4,14b-tetrahydro-10-methyl-2H,10H-pyrazino[2,1-d]pyrrolo[1,2-b] [1,2,5]-benzotriazepine and its derivatives. Farmaco 1992, 47, 987-999.
28. (h) Corelli, F.; Artico, M.; Massa, S.; Stefancich, G. Pyrrolodiazepines and related systems of pharmaceuticals interest via intramolecular cyclizaztion reactions. Trends Heterocycl. Chem. 1991, 2, 105-125.
29. Bailey, D. M.; Johnson, R. E.; Albertson, N. F. Ethyl pyrrole-2-carboxylate. Org. Synth. 1971, 51, 100-102.
30. Keller, W. E. Phase Transfer Reactions; Georg Thieme Verlag: Göppingen, Germany, 1986.
31. Basford, R. E. Preparation and properties of brain mitochondria. Methods Enzymol. 1967, 10, 96-101.
32. Matsumoto, T.; Suzuki, O.; Furuta, T.; Asai, M.; Kurokawa, Y.; Rimura, Y.; Katsumata, Y.; Takahashi, I. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin. Biochem. 1985, 18, 126-129.